PURPOSE: This study aimed to test the hypothesis that elevated expression of antiapoptotic Bcl-2 family proteins predicts a poor therapeutic response of oropharyngeal squamous cell carcinoma (OPSCC) to concurrent platinum-based chemoradiation therapy. EXPERIMENTAL DESIGN: Levels of Bcl-2, Bcl-XL, and Bcl-w were determined and correlated with resistance to cisplatin in a large panel of cell lines derived from squamous cell carcinoma of the head and neck (HNSCC). Univariate and multivariate analyses were used to evaluate the relationship between Bcl-2 and Bcl-XL expression and disease-free survival following chemoradiation therapy in a uniformly treated cohort of patients with OPSCC. RESULTS: In HNSCC cell lines, high endogenous Bcl-2 expression was associated with increased cisplatin resistance, and experimental overexpression of Bcl-2 promoted cisplatin resistance. In patients, tumors positive for Bcl-2 before treatment had greater risk of treatment failure (hazard ratio, 5.99; 95% confidence interval, 1.73-20.8; P=0.0014). In contrast, endogenous Bcl-XL showed no correlation either with cisplatin sensitivity in the cell line panel in vitro, or with risk of recurrence in vivo (hazard ratio, 1.28; 95% confidence interval, 0.39-4.19; P=0.68). Associations between Bcl-2 expression and other clinical characteristics did not account for the predictive value of Bcl-2. CONCLUSIONS: Immunohistochemical assessment of Bcl-2 in pretreatment biopsy specimens can predict response of advanced OPSCC to concurrent platinum-based chemoradiation. As treatments targeting Bcl-2 and its family members become available, this immunohistochemical assessment could help personalize therapy by identifying a subpopulation of patients with a poor prognosis who might benefit from such treatments.
PURPOSE: This study aimed to test the hypothesis that elevated expression of antiapoptotic Bcl-2 family proteins predicts a poor therapeutic response of oropharyngeal squamous cell carcinoma (OPSCC) to concurrent platinum-based chemoradiation therapy. EXPERIMENTAL DESIGN: Levels of Bcl-2, Bcl-XL, and Bcl-w were determined and correlated with resistance to cisplatin in a large panel of cell lines derived from squamous cell carcinoma of the head and neck (HNSCC). Univariate and multivariate analyses were used to evaluate the relationship between Bcl-2 and Bcl-XL expression and disease-free survival following chemoradiation therapy in a uniformly treated cohort of patients with OPSCC. RESULTS: In HNSCC cell lines, high endogenous Bcl-2 expression was associated with increased cisplatin resistance, and experimental overexpression of Bcl-2 promoted cisplatin resistance. In patients, tumors positive for Bcl-2 before treatment had greater risk of treatment failure (hazard ratio, 5.99; 95% confidence interval, 1.73-20.8; P=0.0014). In contrast, endogenous Bcl-XL showed no correlation either with cisplatin sensitivity in the cell line panel in vitro, or with risk of recurrence in vivo (hazard ratio, 1.28; 95% confidence interval, 0.39-4.19; P=0.68). Associations between Bcl-2 expression and other clinical characteristics did not account for the predictive value of Bcl-2. CONCLUSIONS: Immunohistochemical assessment of Bcl-2 in pretreatment biopsy specimens can predict response of advanced OPSCC to concurrent platinum-based chemoradiation. As treatments targeting Bcl-2 and its family members become available, this immunohistochemical assessment could help personalize therapy by identifying a subpopulation of patients with a poor prognosis who might benefit from such treatments.
Authors: A Giatromanolaki; M Koukourakis; T Zaramboukas; A Skordalaki; P Arapantoni; V Georgoulias; G Fountzilas Journal: Anticancer Res Date: 1998 Nov-Dec Impact factor: 2.480
Authors: Thomas J Belbin; Bhuvanesh Singh; Ilana Barber; Nicholas Socci; Bruce Wenig; Richard Smith; Michael B Prystowsky; Geoffrey Childs Journal: Cancer Res Date: 2002-02-15 Impact factor: 12.701
Authors: Daniele Bergamaschi; Milena Gasco; Louise Hiller; Alexandra Sullivan; Nelofer Syed; Giuseppe Trigiante; Isik Yulug; Marco Merlano; Gianmauro Numico; Alberto Comino; Marlene Attard; Olivier Reelfs; Barry Gusterson; Alexandra K Bell; Victoria Heath; Mahvash Tavassoli; Paul J Farrell; Paul Smith; Xin Lu; Tim Crook Journal: Cancer Cell Date: 2003-04 Impact factor: 31.743
Authors: Meredith S Irwin; Keiichi Kondo; Maria Carmen Marin; Lynn S Cheng; William C Hahn; William G Kaelin Journal: Cancer Cell Date: 2003-04 Impact factor: 31.743
Authors: Shahnaz Begum; Maura L Gillison; M Ali Ansari-Lari; Keerti Shah; William H Westra Journal: Clin Cancer Res Date: 2003-12-15 Impact factor: 12.531
Authors: Douglas K Trask; Gregory T Wolf; Carol R Bradford; Susan G Fisher; Kenneth Devaney; Mark Johnson; Timothy Singleton; Max Wicha Journal: Laryngoscope Date: 2002-04 Impact factor: 3.325
Authors: Mei-Kim Ang; Mihir R Patel; Xiao-Ying Yin; Sneha Sundaram; Karen Fritchie; Ni Zhao; Yufeng Liu; Alex J Freemerman; Matthew D Wilkerson; Vonn Walter; Mark C Weissler; William W Shockley; Marion E Couch; Adam M Zanation; Trevor Hackman; Bhishamjit S Chera; Stephen L Harris; C Ryan Miller; Leigh B Thorne; Michele C Hayward; William K Funkhouser; Andrew F Olshan; Carol G Shores; Liza Makowski; D Neil Hayes Journal: Clin Cancer Res Date: 2011-09-09 Impact factor: 12.531
Authors: Shibu Thomas; Bridget A Quinn; Swadesh K Das; Rupesh Dash; Luni Emdad; Santanu Dasgupta; Xiang-Yang Wang; Paul Dent; John C Reed; Maurizio Pellecchia; Devanand Sarkar; Paul B Fisher Journal: Expert Opin Ther Targets Date: 2012-11-22 Impact factor: 6.902